H.C. Wainwright analyst Raghuram Selvaraju raised the firm’s price target on Brainsway (BWAY) to $24 from $18 and keeps a Buy rating on the shares. The firm cites expansion in the sales multiple derived from its comparable universe of publicly-traded medical technology enterprises for the target boost.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BWAY:
- BrainsWay Initiates Clinical Trial for Alcohol Use Disorder
- Brainsway launches first trial of Deep TMS 360 system for AUD
- Brainsway’s Market Expansion and Strong Revenue Performance Justify Buy Rating
- Brainsway price target raised to $18 from $17 at H.C. Wainwright
- BrainsWay Gains FDA Approval for Adolescent Depression Treatment